Clinical Trials

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

400 enrolled

Lymphoma, Follicular

NCT02996773 2025-11-10

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

LymphoidMyeloidOther hematologic neoplasmSarcoma

50 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Mycobacterium avium-intracellulare Infection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT05371093 2025-10-15

ZUMA-22

Phase 3 Active not recruiting

231 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular

NCT02153580 2025-10-06

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

37 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

26 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07126678 2025-08-17

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Phase NA Recruiting

15 enrolled

Lymphoma, Follicular

NCT01974440 2025-05-25

SELENE

403 enrolled 23 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

23 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular

NCT06757894 2025-01-03

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

50 enrolled

Lymphoma, Follicular

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

169 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04745832 2024-11-04

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Phase 3 Terminated

82 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT06284122 2024-10-15

MorningLyte

Phase 3 Recruiting

790 enrolled

Lymphoma, Follicular

NCT00991211 2024-08-22

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

549 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05848765 2023-11-29

REFRACT

Phase 2 Recruiting

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT02733042 2023-11-18

FUSION NHL 001

106 enrolled 48 charts

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05934097 2023-07-06

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Phase 2 Completed

289 enrolled 34 charts

Lymphoma, Lymphoma, Follicular

NCT02257242 2023-02-09

BRiM

11 enrolled 20 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02063685 2022-06-21

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

807 enrolled

Lymphoma, Follicular

NCT00794638 2021-07-02

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

9 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04934930 2021-06-22

FLMRD

Phase 2 Unknown

40 enrolled

Lymphoma, Follicular

NCT02596971 2021-05-24

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

91 enrolled 27 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01234766 2021-05-18

Fol-BRITe

Phase 2 Completed

39 enrolled 6 charts

Lymphoma, Follicular

NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Phase 3 Withdrawn

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2 Terminated

14 enrolled 10 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01059630 2020-01-13

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

413 enrolled 34 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

DermatologicLymphoidOther hematologic neoplasmPlasma cell

43 enrolled 18 charts

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01429025 2019-10-08

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

26 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02187861 2019-06-05

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Phase 2 Completed

163 enrolled 30 charts

Lymphoma, Follicular

NCT00880815 2019-06-03

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

60 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00987493 2019-05-15

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

49 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02008006 2019-01-08

BENEFIT

Phase 2 Terminated

21 enrolled

Lymphoma, Follicular

NCT02240719 2019-01-04

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled

Hodgkin Disease, Lymphoma, Follicular, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01732926 2018-11-16

Bridalveil

Phase 3 Terminated

475 enrolled 9 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled